BJMO - volume 8, issue 5, november 2014
B. Hiddinga MD, J.P. Van Meerbeeck MD, PhD
This report will highlight 10 important studies presented during ESMO 2014, and 4 small but promising future directions in the treatment of NSCLC. The presidential symposium featured two negative studies in a large cohort of non-small cell lung cancer (NSCLC) patients: the MAGRIT and IMPRESS. The other topics include immunotherapy, targeted treatment and biomarkers, development of new drugs in ALK-EML rearranged NSCLC, and prevention of cachexia in NSCLC. Lastly, an important study in malignant pleural mesothelioma (MPM) was presented.
(BELG J MED ONCOL 2014;8(4):152–7)
Read moreBJMO - volume 8, issue 5, november 2014
M. Peeters MD, PhD, K. Papadimitriou MD, PhD
From 26 till 30 September 2014, the 30th yearly ESMO meeting took place in Madrid. The theme for ESMO 2014 was ‘Precision Medicine in Cancer Care.’ This report will highlight the key studies presented during the meeting, with special focus on gastrointestinal cancer.
(BELG J MED ONCOL 2014;8(4):158–62)
Read moreBJMO - volume 8, issue 5, november 2014
L. Decoster MD, PhD
The 2014 annual meeting of the European Society for Medical Oncology (ESMO) featured a number of interesting studies in endocrine and neuroendocrine oncology. This report will first focus on two presentations regarding lenvatinib in the treatment of thyroid cancers. In addition to this, the final OS of the RADIANT-3 study, evaluating everolimus in patients with advanced pancreatic neuroendocrine tumours (NET), will be summarized. The last part of the report will focus on the molecular profiling of NETs and discusses a study assessing the quality of life in NET patients using lanreotide autogel.
(BELG J MED ONCOL 2014;8(4):163–5)
Read moreBJMO - volume 8, issue 5, november 2014
H. Wildiers MD, PhD, Tom Feys MBA, MSc
(BELG J MED ONCOL 2014;8(4):166–70)
Read moreBJMO - volume 8, issue 5, november 2014
B. Neyns MD, PhD
(BELG J MED ONCOL 2014;8(4):171–6)
Read moreBJMO - volume 8, issue 5, november 2014
J. De Grève MD, PhD
(BELG J MED ONCOL 2014;8(4):177–9)
Read moreBJMO - volume 8, issue 5, november 2014
P. Specenier MD, PhD
This report will discuss the key lectures on head and neck cancer (HNC) presented during the 2014 annual meeting of the European Society for Medical Oncology. After addressing the novelties in immunotherapeutic therapy for HNC, the top stories on news promising drugs will be discussed. In addition some presentations discussing the set up and implementation of practice guidelines in HNC will be addressed to end of with some innovations on biomarkers.
(BELG J MED ONCOL 2014;8(4):180–3)
Read more
Top
